Arcus Biosciences, Inc. RCUS

US Biotechnology

$18.68 ▼ -1.42% ($-0.27)

Open $18.89

Prev Close $18.95

Day Range $18.52 – $19.27

52W Range $17.43 – $31.74

Market Cap $2.59B

Beta 1.12

EPS (TTM) $-3.90

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NEW YORK STOCK EXCHANGE, INC.
Currency	USD
IPO Date	2018-03-15
Shares Out.	143,450,000
Website	arcusbio.com/ ↗
Phone	13026974590
Employees	601
Revenue	$9.0M
Gross Profit	$9.0M
Net Income	-$128.0M
Free Cash Flow	-$466.0M
Total Assets	$818.0M
Total Liabilities	$460.0M
Equity	$358.0M

About Arcus Biosciences, Inc.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Arcus Biosciences, Inc. is a publicly traded company under the ticker symbol RCUS on the NEW YORK STOCK EXCHANGE, INC., operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.